ZA200202905B - Formulation of substituted benzimidazoles. - Google Patents

Formulation of substituted benzimidazoles. Download PDF

Info

Publication number
ZA200202905B
ZA200202905B ZA200202905A ZA200202905A ZA200202905B ZA 200202905 B ZA200202905 B ZA 200202905B ZA 200202905 A ZA200202905 A ZA 200202905A ZA 200202905 A ZA200202905 A ZA 200202905A ZA 200202905 B ZA200202905 B ZA 200202905B
Authority
ZA
South Africa
Prior art keywords
sodium
liquid formulation
stable liquid
potassium salt
formulation according
Prior art date
Application number
ZA200202905A
Other languages
English (en)
Inventor
Mikael Bruells
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200202905B publication Critical patent/ZA200202905B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200202905A 1999-10-22 2002-04-12 Formulation of substituted benzimidazoles. ZA200202905B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
ZA200202905B true ZA200202905B (en) 2003-07-14

Family

ID=20417464

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202905A ZA200202905B (en) 1999-10-22 2002-04-12 Formulation of substituted benzimidazoles.

Country Status (35)

Country Link
US (1) US6730685B1 (enExample)
EP (1) EP1274427B1 (enExample)
JP (1) JP2003512327A (enExample)
KR (1) KR100785603B1 (enExample)
CN (1) CN1213751C (enExample)
AR (1) AR029005A1 (enExample)
AT (1) ATE304851T1 (enExample)
AU (1) AU782866B2 (enExample)
BG (1) BG65580B1 (enExample)
BR (1) BR0014895A (enExample)
CA (1) CA2425199C (enExample)
CO (1) CO5261533A1 (enExample)
CY (1) CY1106055T1 (enExample)
CZ (1) CZ20021375A3 (enExample)
DE (1) DE60022789T2 (enExample)
DK (1) DK1274427T3 (enExample)
EE (1) EE05175B1 (enExample)
ES (1) ES2246903T3 (enExample)
HU (1) HUP0203121A3 (enExample)
IL (2) IL149107A0 (enExample)
IS (1) IS2196B (enExample)
MX (1) MXPA02003900A (enExample)
MY (1) MY131971A (enExample)
NO (1) NO329545B1 (enExample)
NZ (1) NZ518155A (enExample)
PL (1) PL199868B1 (enExample)
RU (1) RU2286782C2 (enExample)
SE (1) SE9903831D0 (enExample)
SI (1) SI1274427T1 (enExample)
SK (1) SK286266B6 (enExample)
TR (1) TR200201103T2 (enExample)
TW (1) TWI236372B (enExample)
UA (1) UA74347C2 (enExample)
WO (1) WO2001028558A1 (enExample)
ZA (1) ZA200202905B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001276721A1 (en) * 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
WO2002015908A1 (en) * 2000-08-18 2002-02-28 Takeda Chemical Industries, Ltd. Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CN100558726C (zh) * 2003-02-24 2009-11-11 田边三菱制药株式会社 泰妥拉唑的对映体及其在治疗中的应用
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060089376A1 (en) * 2004-10-27 2006-04-27 Joshi Ramesh A Tenatoprazole salts and process of preparation thereof
AU2007248949B2 (en) * 2006-05-09 2010-04-08 Astrazeneca Ab Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
JP6698651B2 (ja) 2014-11-13 2020-05-27 スリーエム イノベイティブ プロパティズ カンパニー 試料中の細菌atpを検出するためのatp−ジホスホヒドロラーゼを含むキット
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2025078989A1 (en) * 2023-10-11 2025-04-17 Reena Patel Stabilized pharmaceutical compositions
WO2025181379A1 (en) * 2024-03-01 2025-09-04 Etico Lifesciences Private Limited Liquid, storage stable, directly injectable, pantoprazole formulations, their uses and manufacturing

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DK399389A (da) 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SG52479A1 (en) 1992-07-28 1998-09-28 Astra Ab Injection and injection kit containing omeprazole and its analogs
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TW359614B (en) 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions

Also Published As

Publication number Publication date
IL149107A (en) 2008-04-13
US6730685B1 (en) 2004-05-04
IS6347A (is) 2002-04-17
MXPA02003900A (es) 2002-09-30
CY1106055T1 (el) 2011-04-06
CO5261533A1 (es) 2003-03-31
ES2246903T3 (es) 2006-03-01
PL354926A1 (en) 2004-03-22
TWI236372B (en) 2005-07-21
CA2425199C (en) 2010-12-07
CZ20021375A3 (cs) 2002-09-11
HUP0203121A3 (en) 2004-01-28
EE200200204A (et) 2003-04-15
CA2425199A1 (en) 2001-04-26
BG65580B1 (bg) 2009-01-30
KR100785603B1 (ko) 2007-12-14
BG106602A (en) 2002-12-29
HK1051142A1 (en) 2003-07-25
PL199868B1 (pl) 2008-11-28
SK5392002A3 (en) 2002-10-08
BR0014895A (pt) 2002-06-18
AR029005A1 (es) 2003-06-04
RU2286782C2 (ru) 2006-11-10
CN1213751C (zh) 2005-08-10
SK286266B6 (sk) 2008-06-06
NO329545B1 (no) 2010-11-08
HUP0203121A2 (hu) 2003-01-28
KR20020059637A (ko) 2002-07-13
AU1182301A (en) 2001-04-30
DK1274427T3 (da) 2005-12-27
SE9903831D0 (sv) 1999-10-22
TR200201103T2 (tr) 2002-08-21
IL149107A0 (en) 2002-11-10
EE05175B1 (et) 2009-06-15
ATE304851T1 (de) 2005-10-15
NO20021860D0 (no) 2002-04-19
UA74347C2 (uk) 2005-12-15
NO20021860L (no) 2002-05-21
IS2196B (is) 2007-01-15
WO2001028558A1 (en) 2001-04-26
CN1382048A (zh) 2002-11-27
SI1274427T1 (sl) 2006-02-28
EP1274427A1 (en) 2003-01-15
NZ518155A (en) 2004-07-30
JP2003512327A (ja) 2003-04-02
AU782866B2 (en) 2005-09-01
MY131971A (en) 2007-09-28
DE60022789D1 (de) 2006-02-02
DE60022789T2 (de) 2006-06-22
EP1274427B1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
CA2425199C (en) Formulation of substituted benzimidazoles
KR100258423B1 (ko) 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트
US5536735A (en) Pharmaceutical composition
SK6062003A3 (en) Freeze-dried pantoprazole preparation and pantoprazole injection
JPWO2006134877A1 (ja) 注射剤
JPH02655A (ja) 置換ジヒドロピリジンカルシウムチヤンネルブロツカー用の持続性解放放出系
JP6923122B2 (ja) 難溶性複合物又はその溶媒和物、薬物組成物及びその応用
JP2006501313A (ja) (s)−パントプラゾールの塩及びその水和物
ES2232459T3 (es) Derivados de benzimidazol antiulcerosos estables frente a los acidos de administracion oral.
JPH0576929B2 (enExample)
HK1051142B (en) Formulation of substituted benzimidazoles
SK51298A3 (en) Pharmaceutical compositions containing platelet aggregation inhibitors
JPH07157440A (ja) 医薬用組成物
TH58082A (th) สารสูตรผสมของอีโพธิโลนอะนาลอกสำหรับนอกทางปาก